Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 11/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 10/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.42 |
| ▸ | QPCT | Q16769 | 1/20 | 0.42 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.42 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11007511 | 0.80 | CYP19A1 (0.56) | CYP19A1POLBCYP11B1CYP11B2CYP1A2 | |
| SCHEMBL4427091 | 0.78 | PDE10A (0.42) | PDE10AMAPTNPC1RAB9A | |
| SCHEMBL4428136 | 0.77 | PDE10A (0.61) | PDE10ACYP1A2CYP3A4MAPTNPC1 | |
| SCHEMBL4422196 | 0.76 | PDE10A (0.41) | PDE10ACYP1A2NPC1RAB9A | |
| SCHEMBL26666217 | 0.75 | NPC1 (0.59) | CYP19A1CYP11B1CYP11B2CYP1A2CYP3A4 | |
| SCHEMBL28509060 | 0.70 | CYP11B1 (0.57) | CYP19A1PDE10APOLBCYP11B1CYP11B2 | |
| SCHEMBL31061448 | 0.69 | CYP19A1 (0.49) | CYP19A1PDE10ACYP11B1CYP11B2TBXAS1 | |
| Benzylimidazole SCHEMBL28213650 | 0.68 | CYP11B1 (0.71) | CYP19A1POLBCYP11B1CYP11B2CYP1A2 | |
| Hydrochloric Acid SCHEMBL4433511 | 0.68 | IDO1 (0.56) | CYP19A1POLBCYP11B1CYP11B2CYP1A2 | |
| Hydrochloric Acid SCHEMBL7161630 | 0.68 | IDO1 (0.56) | CYP19A1POLBCYP11B1CYP11B2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101798298-B | Imidazole derivatives | HOFFMANN LA ROCHE | 2013-01-09 | — | — | CN | disclosed |
| CN-101798298-A | Imdazole derivatives | HOFFMANN LA ROCHE | 2010-08-11 | — | — | CN | disclosed |
| CN-1489580-B | Imidazole derivatives | HOFFMANN LA ROCHE | 2010-05-26 | — | — | CN | disclosed |
| EP-1358165-B1 | IMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-03-11 | — | — | EP | disclosed |
| CN-1489580-A | Imidazole derivatives | - | 2004-04-14 | — | — | CN | disclosed |
| US-6683097-B2 | AFFINITY TO NMDA (N-METHYL-D-ASPARTATE)-RECEPTOR SUBTYPE SELECTIVE BLOCKERS; MEDIATING PROCESSES UNDERLYING DEVELOPMENT OF CENTRAL NERVOUS SYSTEM AS WELL AS LEARNING AND MEMORY FORMATION | HOFFMANN-LA ROCHE INC. | 2004-01-27 | — | — | US | disclosed |
| US-6667335-B2 | NMDA (N-methyl-D-aspartate)-receptor subtype selective blockers | HOFFMANN-LA ROCHE INC. | 2003-12-23 | — | — | US | disclosed |
| US-20030191311-A1 | A 5-(imidazol-1-yl-methyl)-pyridine derivatives for treating an NMDA-receptor-mediated disease, neurodegeneration disorder caused by stroke or brain trauma, Alzheimer's disease, Parkinson's disease, Huntington's disease | EVOTEC INTERNATIONAL GMBH (DE) | 2003-10-09 | — | — | US | disclosed |
| US-20030187268-A1 | Imidazole derivatives | EVOTEC INTERNATIONAL GMBH (DE) | 2003-10-02 | — | — | US | disclosed |
| US-6610723-B2 | Such as 3-(3,4-dimethyl-phenyl)-5-(2-methyl-imidazol-1-yl-methyl)-pyridine having affinity to N-methyl-D-aspartate-receptor subtype selective blockers; central nervous system; learning, memory, neurodegeneration | HOFFMANN-LA ROCHE INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020151715-A1 | Imidazole derivatives | EVOTEC INTERNATIONAL GMBH (DE) | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191311-A1 | A 5-(imidazol-1-yl-methyl)-pyridine derivatives for treating an NMDA-receptor-mediated disease, neurodegeneration disorder caused by stroke or brain trauma, Alzheimer's disease, Parkinson's disease, Huntington's disease | GRIN1, GRIN2B, GRIN3B | CYP19A1 4831/4885PDE10A 2202/4885POLB 3234/4885 |
| US-20020151715-A1 | Imidazole derivatives | GRIN2B, GRIN1, GRIN2A | CYP19A1 4804/4885PDE10A 1675/4885POLB 3015/4885 |
| US-20030187268-A1 | Imidazole derivatives | GRIN2B, GRIN1, GRIN2A | CYP19A1 4804/4885PDE10A 1675/4885POLB 3015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.